Targeted panel testing superior for neuromuscular diseases
(HealthDay)—Targeted panel testing has the highest clinical yield for molecular diagnosis of neuromuscular diseases (NMDs), according to a study published in the February issue of the Annals of Neurology.
Feb 13, 2015
0
3